etravirine has been researched along with suvorexant in 1 studies
| Studies (etravirine) | Trials (etravirine) | Recent Studies (post-2010) (etravirine) | Studies (suvorexant) | Trials (suvorexant) | Recent Studies (post-2010) (suvorexant) |
|---|---|---|---|---|---|
| 572 | 90 | 321 | 214 | 47 | 200 |
| Protein | Taxonomy | etravirine (IC50) | suvorexant (IC50) |
|---|---|---|---|
| Orexin receptor type 1 | Homo sapiens (human) | 0.0873 | |
| Orexin receptor type 2 | Homo sapiens (human) | 0.0613 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Converso, A; Daublain, P; El Marrouni, A; Kesisoglou, F; Lipert, MP; Templeton, AC; Wuelfing, WP | 1 |
1 other study(ies) available for etravirine and suvorexant
| Article | Year |
|---|---|
Dose Number as a Tool to Guide Lead Optimization for Orally Bioavailable Compounds in Drug Discovery.
Topics: Administration, Oral; Animals; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Drug Discovery; Humans; Oral Mucosal Absorption; Pharmaceutical Preparations; Solubility | 2022 |